Press Releases

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase of ischemic stroke and thrombotic diseases, today announces the completion of recruitment in GARDEN, its phase 2 clinical study on the use of glenzocimab, a novel humanized monoclonal antibody fragment, in patients with COVID-19- induced […]
Read more

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces the end of recruitment in ACTIMIS, its phase 1b/2a study with glenzocimab (ACT017), a novel humanized monoclonal antibody fragment for use in patients with acute ischemic stroke. ACTIMIS (NCT03803007) is a multinational, multicenter, […]
Read more

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Paris, June 15 th, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers. Mrs Sophie Binay and Mr […]
Read more

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

– Approval of phase 2 GARDEN study in France and Brazil – GARDEN will enroll 60 patients hospitalized for COVID19 – First Patient included at University Hospital of Strasbourg Paris, December 22th, 2020 ​– Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announces […]
Read more

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Paris, October 1st, 2020 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully […]
Read more

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

UN PROGRAMME NATIONAL POUR PROMOUVOIR ET ACCOMPAGNER LES FUTURS LEADERS TECHNOLOGIQUES DANS LEUR DEVELOPPEMENT INTERNATIONAL Paris, le 21 janvier 2020 – ACTICOR Biotech, société de biotechnologie en phase clinique impliquée dans la phase aiguë des maladies thrombotiques, y compris les accidents vasculaires cérébraux ischémiques aigus, annonce aujourd’hui avoir intégré la première promotion du French Tech […]
Read more
Page 1 of 512345